细胞疗法治疗大便失禁的现状及展望

doi:10.3969/j.issn.1000-8535.2022.06.001

广州医药 ›› 2022, Vol. 53 ›› Issue (6): 1-6.DOI: 10.3969/j.issn.1000-8535.2022.06.001

• 专家综述 • 下一篇

细胞疗法治疗大便失禁的现状及展望

陈文斌, 李旺林

华南理工大学附属第二医院,广州市第一人民医院结直肠肛门外科(广州 510180)

收稿日期:2022-06-21 出版日期:2022-11-20 发布日期:2022-11-30
通讯作者: 李旺林,E-mail:421255910@qq.com
作者简介:李旺林,博士,主任医师/教授,博士生导师。美国哈佛大学博士后,美国克利夫兰医疗中心访问学者,广州市高层次卫生人才,广州市医学重点人才,广东省杰出青年医学人才,岭南名医,羊城好医生。现为中国抗癌协会康复分会学术指导委员会副主委,中国抗癌协会微生态营养学组副组长,广州医师协会普外科分会主委,广东省医师协会胃肠外科分会副主委,广东省精准医学应用学会结直肠癌分会副主委,广东省医学会结直肠肛门疾病学组副组长,广州医学会胃肠外科分会副主委。任《中华炎性肠病杂志》《广州医药》编委,Annal of Laparoscopic and Endoscopic Surgery客座编委,Journal of Nutritional Oncology《中华实验外科杂志》《实用医学杂志》特约审稿专家。
主要研究方向为结直肠癌的分子生物学研究和肠道微生态与肠道炎症的关系研究。擅长结直肠癌微创腹腔镜手术治疗,尤其是低位直肠癌保肛手术治疗。在国内较早进行单孔腹腔镜和单孔+1腹腔镜结直肠手术探索,国际上最早进行双手套单孔taTME手术探索,并自主创新性地提出简易taTME手术。主持或主要参与国家省市各类课题20余项,迄今发表SCI等学术论文100余篇,其中第一作者/通信作者SCI论文33篇。主编《肿瘤微生态学》专著1部,参编专著4部,参与国家级指南编写4部。获得广东省医学科学一等奖1项,广东省科技进步二等奖1项,广州市科技进步一等奖1项。
基金资助:
广东省粤穗联合基金(2021B1515420004);广州市科技计划项目(202201020363);广州市临床特色技术项目(2019TS52)

Current status and prospect of cell therapy for fecal incontinence

CHEN Wenbin, LI Wanglin

Department of Colorectal and Anal Surgery, Guangzhou First People's Hospital, the Second Affiliated Hospital, South China University of Technology, Guangzhou 510180, China

Received:2022-06-21 Online:2022-11-20 Published:2022-11-30

摘要/Abstract

摘要： 大便失禁是肛肠外科常见疾病,可导致患者生活质量下降,并引起一系列社会心理问题,其发病率随着年龄增加明显上升。肛门括约肌复合体损伤是大便失禁的最常见原因。目前的治疗方式包括保守治疗和手术治疗,但治疗效果仍不理想,尤其是长期治疗效果较差。最近,许多临床前和临床研究对大便失禁的干细胞疗法进行了探索,作为一种新的治疗方式,干细胞疗法有望彻底治愈大便失禁。本文就干细胞疗法治疗大便失禁的动物模型、损伤和修复机制、疗效等方面进行综述。

关键词: 细胞疗法, 大便失禁, 疗效, 机制

Abstract: Fecal incontinence is a common anorectal surgical condition that can lead to decreased quality of life and a range of psychosocial problems in patients, and its incidence increases significantly with age. Damage to the anal sphincter complex is the most common cause of fecal incontinence. Current treatment modalities include conservative and surgical treatment, but treatment outcomes remain suboptimal, especially in the long term. Recently, many preclinical and clinical studies have explored stem cell therapy for fecal incontinence as a new treatment modality that holds promise for a complete cure of fecal incontinence. This paper presents a review of animal models, mechanisms of injury and repair, and efficacy of stem cell therapy for fecal incontinence.

Key words: cell therapy, fecal incontinence, therapeutic effect, mechanism

陈文斌, 李旺林. 细胞疗法治疗大便失禁的现状及展望[J]. 广州医药, 2022, 53(6): 1-6.

CHEN Wenbin, LI Wanglin. Current status and prospect of cell therapy for fecal incontinence[J]. Guangzhou Medical Journal, 2022, 53(6): 1-6.

参考文献

[1] MADOFF R D, PARKER S C, VARMA M G, et al. Faecal incontinence in adults[J]. Lancet, 2004,364(9434):621-632.
[2] 陆立, 苏丹, 李丽, 等. 骶神经调节术治疗大便失禁的研究进展[J]. 结直肠肛门外科, 2021,27(5):435-437.
[3] WALD A. Diagnosis and management of fecal incontinence[J]. Curr Gastroenterol Rep, 2018,20(3):9.
[4] BALAPHAS A, MEYER J, MEIER R, et al. Cell therapy for anal sphincter incontinence: Where do we stand?[J]. Cells, 2021,10(8):2086.
[5] 苗为民, 曹冬兴, 叶光耀, 等. 大便失禁的外科治疗技术研究进展[J]. 结直肠肛门外科, 2021,27(5):428-431.
[6] TREBOL J, CARABIAS-ORGAZ A, GARCIA-ARRANZ M, et al. Stem cell therapy for faecal incontinence: Current state and future perspectives[J]. World J Stem Cells, 2018,10(7):82-105.
[7] PAQUETTE I M, VARMA M G, KAISER A M, et al. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal Incontinence[J]. Dis Colon Rectum, 2015,58(7):623-636.
[8] 姚一博, 肖长芳, 王琛. 大便失禁的非手术治疗研究进展[J]. 结直肠肛门外科, 2021,27(5):423-427.
[9] KHAFAGY W W, EL SAID M M, THABET W M, et al. Evaluation of anatomical and functional results of overlapping anal sphincter repair with or without the injection of bone marrow aspirate concentrate: A case-control study[J]. Colorectal Dis, 2017,19(1):O66-O74.
[10] FRUDINGER A, MARKSTEINER R, PFEIFER J, et al. Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence[J]. Stem Cell Res Ther, 2018,9(1):233.
[11] 董青军, 梁宏涛, 王琛, 等. 大便失禁的诊治策略[J]. 中国医药导报, 2018,15(24):26-29.
[12] ELMI A, KAJBAFZADEH A M, OGHABIAN M A, et al. Anal sphincter repair with muscle progenitor cell transplantation: Serial assessment with iron oxide-enhanced MRI[J]. Am J Roentgenol, 2014,202(3):619-625.
[13] KAJBAFZADEH A M, ELMI A, TALAB S S, et al. Functional external anal sphincter reconstruction for treatment of anal incontinence using muscle progenitor cell auto grafting[J]. Dis Colon Rectum, 2010,53(10):1415-1421.
[14] OH H, LEE H S, LEE J H, et al. Functional and histological evidence for the targeted therapy using biocompatible polycaprolactone beads and autologous myoblasts in a dog model of fecal incontinence[J]. Dis Colon Rectum, 2015,58(5):517-525.
[15] OH H, LEE H S, LEE J H, et al. Coadministration of basic fibroblast growth factor-loaded polycaprolactone beads and autologous myoblasts in a dog model of fecal incontinence[J]. Int J Colorectal Dis, 2015,30(4):549-557.
[16] MAZZANTI B, LORENZI B, BORGHINI A, et al. Local injection of bone marrow progenitor cells for the treatment of anal sphincter injury: in-vitro expanded versus minimally-manipulated cells[J]. Stem Cell Res Ther, 2016,7(1):85.
[17] CHEN W, HE Z, LI S, et al. The effect of mesenchymal stem cells, adipose tissue derived stem cells, and cellular stromal vascular fraction on the repair of acute anal sphincter injury in rats[J]. Bioengineering (Basel), 2022,9(318):318.
[18] SUN L, XIE Z, KUANG M, et al. Regenerating the anal sphincter: Cytokines, stem cells, or both?[J]. Dis Colon Rectum, 2017,60(4):416-425.
[19] BISSON A, FRERET M, DROUOT L, et al. Restoration of anal sphincter function after myoblast cell therapy in incontinent rats[J]. Cell Transplant, 2015,24(2):277-286.
[20] SALCEDO L, MAYORGA M, DAMASER M, et al. Mesenchymal stem cells can improve anal pressures after anal sphincter injury[J]. Stem Cell Res, 2013,10(1):95-102.
[21] SALCEDO L, DAMASER M, BUTLER R, et al. Long-term effects on pressure and electromyography in a rat model of anal sphincter injury[J]. Dis Colon Rectum, 2010,53(8):1209-1217.
[22] MONTOYA T I, ACEVEDO J F, SMITH B, et al. Myogenic stem cell-laden hydrogel scaffold in wound healing of the disrupted external anal sphincter[J]. Int Urogynecol J, 2015,26(6):893-904.
[23] KAJBAFZADEH A M, KAJBAFZADEH M, SABETKISH S, et al. Tissue-engineered external anal sphincter using autologous myogenic satellite cells and extracellular matrix: Functional and histological studies[J]. Ann Biomed Eng, 2016,44(5):1773-1784.
[24] ZUTSHI M, SALCEDO L B, ZASZCZURYNSKI P J, et al. Effects of sphincterotomy and pudendal nerve transection on the anal sphincter in a rat model[J]. Dis Colon Rectum, 2009,52(7):1321-1329.
[25] PLAIR A, BENNINGTON J, WILLIAMS J K, et al. Regenerative medicine for anal incontinence: A review of regenerative therapies beyond cells[J]. Int Urogynecol J, 2021,32(9):2337-2347.
[26] 郭慧平,SUNWEIMING. 大便失禁的病理机制初探[J]. 中华消化杂志, 1997(S1):15.
[27] LORENZI B, PESSINA F, LORENZONI P, et al. Treatment of experimental injury of anal sphincters with primary surgical repair and injection of bone marrow-derived mesenchymal stem cells[J]. Dis Colon Rectum, 2008,51(4):411-420.
[28] 李鹏, 金文琪, 李小嘉, 等. 温和灸联合间充质干细胞移植对大鼠损伤肛门括约肌功能的修复[J]. 中国中医急症, 2020,29(12):2087-2091.
[29] PATHI S D, ACEVEDO J F, KELLER P W, et al. Recovery of the injured external anal sphincter after injection of local or intravenous mesenchymal stem cells[J]. Obstet Gynecol, 2012,119(1):134-144.
[30] KANG S B, LEE H N, LEE J Y, et al. Sphincter contractility after muscle-derived stem cells autograft into the cryoinjured anal sphincters of rats[J]. Dis Colon Rectum, 2008,51(9):1367-1373.
[31] SAIHARA R, KOMURO H, URITA Y, et al. Myoblast transplantation to defecation muscles in a rat model: A possible treatment strategy for fecal incontinence after the repair of imperforate anus[J]. Pediatr Surg Int, 2009,25(11):981-986.
[32] CRAIG J B, LANE F L, NISTOR G, et al. Allogenic myoblast transplantation in the rat anal sphincter[J]. Female Pelvic Med Reconstr Surg, 2010,16(4):205-208.
[33] KANG S, LEE H S, LIM J, et al. Injection of porous polycaprolactone beads containing autologous myoblasts in a dog model of fecal incontinence[J]. J Korean Surg Soc, 2013,84(4):216.
[34] JACOBS S A, LANE F L, PHAM Q A, et al. Safety assessment of myogenic stem cell transplantation and resulting tumor formation[J]. Female Pelvic Med Reconstr Surg, 2013,19(6):362-368.
[35] 包喜军, 李玲, 秦海斌, 等. 脂肪干细胞的研究现状及其在犬病诊疗上的应用前景[J]. 畜牧与兽医, 2022,54(5):139-145.
[36] TRBOL J, GEORGIEV-HRISTOV T, VEGA-CLEMENTE L, et al. Rat model of anal sphincter injury and two approaches for stem cell administration[J]. World J Stem Cells, 2018,10(1):1-14.
[37] KUISMANEN K, JUNTUNEN M, NARRA G N, et al. Functional outcome of human adipose stem cell injections in rat anal sphincter acute injury model[J]. Stem Cells Transl Med, 2018,7(3):295-304.
[38] de la PORTILLA F, GUERRERO J L, MAESTRE M V, et al. Treatment of faecal incontinence with autologous expanded mesenchymal stem cells: results of a pilot study[J]. Colorectal Dis, 2021,23(3):698-709.
[39] PARK E J, KANG J, BAIK S H. Treatment of faecal incontinence using allogeneic-adipose-derived mesenchymal stem cells: A study protocol for a pilot randomised controlled trial[J]. BMJ Open, 2016,6(2):e10450.
[40] RAGHAVAN S, MIYASAKA E A, GILMONT R R, et al. Perianal implantation of bioengineered human internal anal sphincter constructs intrinsically innervated with human neural progenitor cells[J]. Surgery, 2014,155(4):668-674.
[41] de LIGNY W R, KERKHOF M H, RUIZ-ZAPATA A M. Regenerative medicine as a therapeutic option for fecal incontinence: a systematic review of preclinical and clinical studies[J]. Am J Obstet Gynecol, 2019,220(2):142-154.
[42] CAPLAN A I, DENNIS J E. Mesenchymal stem cells as trophic mediators[J]. J Cell Biochem, 2006,98(5):1076-1084.
[43] FAN X L, ZHANG Z, MA C Y, et al. Mesenchymal stem cells for inflammatory airway disorders: Promises and challenges[J]. Biosci Rep, 2019,39(1):bsr2018-2160.
[44] NAKAMURA Y, MIYAKI S, ISHITOBI H, et al. Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration[J]. FEBS Lett, 2015,589(11):1257-1265.
[45] GRAS S, TOLSTRUP C K, LOSE G. Regenerative medicine provides alternative strategies for the treatment of anal incontinence[J]. Int Urogynecol J, 2017,28(3):341-350.
[46] LI P, MA X, JIN W, et al. Effects of local injection and intravenous injection of allogeneic bone marrow mesenchymal stem cells on the structure and function of damaged anal sphincter in rats[J]. J Tissue Eng Regen Med, 2020,14(7):989-1000.
[47] SALCEDO L, PENN M, DAMASER M, et al. Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells[J]. Stem Cells Transl Med, 2014,3(6):760-767.
[48] LANE F L, JACOBS S A, CRAIG J B, et al. In vivo recovery of the injured anal sphincter after repair and injection of myogenic stem cells: An experimental model[J]. Dis Colon Rectum, 2013,56(11):1290-1297.
[49] BOYER O, BRIDOUX V, GIVERNE C, et al. Autologous myoblasts for the treatment of fecal incontinence: Results of a phase 2 randomized placebo-controlled study (MIAS)[J]. Ann Surg, 2018,267(3):443-450.
[50] FRUDINGER A, KOLLE D, SCHWAIGER W, et al. Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up[J]. Gut, 2010,59(1):55-61.
[51] FRUDINGER A, PFEIFER J, PAEDE J, et al. Autologous skeletal-muscle-derived cell injection for anal incontinence due to obstetric trauma: A 5-year follow-up of an initial study of 10 patients[J]. Colorectal Dis, 2015,17(9):794-801.

细胞疗法治疗大便失禁的现状及展望

Current status and prospect of cell therapy for fecal incontinence

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄娟, 温雅, 张华根, 朱旭华, 曾汉华. 支气管镜下肺泡灌洗阿米卡星治疗老年支气管扩张合并感染患者的疗效[J]. 广州医药, 2022, 53(6): 31-35.
[2]	蔡强, 张苗, 黄朝情, 张荣, 杨蕾, 王宗权. 基于网络药理学预测黄甲软肝颗粒抗肝纤维化作用及验证研究[J]. 广州医药, 2022, 53(6): 119-127.
[3]	黎子武, 梁林国, 杨均秀, 陈强锋, 郑志坚. 重组人干扰素α 2b喷雾剂治疗儿童流行性感冒的疗效及安全性评价[J]. 广州医药, 2022, 53(5): 76-79.
[4]	邱凌骐, 邱浩强, 陈松深. 美多巴联合盐酸司来吉兰治疗帕金森患者的临床效果及影响[J]. 广州医药, 2022, 53(5): 97-100.
[5]	钟亮, 刘清壮, 蔡茂德. 信迪利单抗联合化疗治疗复发转移食管癌的临床疗效[J]. 广州医药, 2022, 53(5): 130-133.
[6]	张爱婷, 赵素霞, 刘文娟, 岳丽丹, 贾秀梅. 羌活胜湿汤对风湿外感头痛患者的疗效分析[J]. 广州医药, 2022, 53(4): 65-68.
[7]	杨彤, 陈勇, 王洁, 何德英, 任毅. 心脉通治疗冠心病临床随机对照试验的系统评价[J]. 广州医药, 2022, 53(4): 118-124.
[8]	许嘉月, 蔡桂元, 兰月. 经颅磁刺激在神经康复中的应用[J]. 广州医药, 2022, 53(3): 1-6.
[9]	谢汉清, 黄钻明, 杨艳萍, 胡寿祥. 电视胸腔镜手术与传统开胸手术在胸腺瘤治疗中的临床疗效对比分析[J]. 广州医药, 2022, 53(3): 131-133.
[10]	李俊. 补阳还五汤加减治疗肾病综合征的疗效及临床价值[J]. 广州医药, 2022, 53(2): 48-51.
[11]	刘志伟, 黄志荣. 雾化吸入干扰素-α治疗儿童疱疹性咽峡炎临床疗效评价[J]. 广州医药, 2022, 53(2): 82-86.
[12]	陈夏. 宫腔镜电切术联合炔诺酮对围绝经期功能失调性子宫出血患者治疗的临床效果[J]. 广州医药, 2022, 53(2): 99-101.
[13]	刘芳, 武明莉, 杨小风, 娄欢, 张颖. 不同保守治疗方法在输卵管妊娠中的治疗分析[J]. 广州医药, 2022, 53(2): 124-127.
[14]	谢汉清, 黄钻明, 杨艳萍, 胡寿祥. 电视胸腔镜手术与传统开胸手术在胸腺瘤治疗中的临床疗效对比[J]. 广州医药, 2022, 53(1): 114-116.
[15]	梁长征, 陈朝兴, 黎卓, 梁聚兴. 口腔种植修复和常规修复在牙列缺损治疗中的有效性分析[J]. 广州医药, 2021, 52(6): 72-75.